Evidence map›Paper›PMID 34744082›Full record

ArticleJournal of Alzheimer's disease : JAD2021

Oleamide, a Sleep-Inducing Supplement, Upregulates Doublecortin in Hippocampal Progenitor Cells via PPARα.

Avik Roy, Madhuchhanda Kundu, Sudipta Chakrabarti, Dhruv R Patel, Kalipada Pahan

Open access · greenAbstract read
In one paragraph

Article in Journal of Alzheimer's disease : JAD, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.7field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Neuroprotective Effect of Solid Lipid Nanoparticles Loaded withNanomaterials (Basel, Switzerland) · 2024
    Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Avik RoyDepartment of Neurological Sciences, Rush University Medical Center, Chicago, IL, USA.
Madhuchhanda KunduDepartment of Neurological Sciences, Rush University Medical Center, Chicago, IL, USA.
Sudipta ChakrabartiDepartment of Neurological Sciences, Rush University Medical Center, Chicago, IL, USA.
Dhruv R PatelDepartment of Neurological Sciences, Rush University Medical Center, Chicago, IL, USA.
Kalipada PahanDepartment of Neurological Sciences, Rush University Medical Center, Chicago, IL, USA.
Rush University Medical Center · US

Funding

Characterizing novel hippocampal drugs for Alzheimer's diseaseR01AG050431 · NIA · RUSH UNIVERSITY MEDICAL CENTER · PI PAHAN, KALIPADA · 2016 to 2020
$2.1M
Intranasal TIDM peptide for tauopathyR21AG069229 · NIA · RUSH UNIVERSITY MEDICAL CENTER · PI PAHAN, KALIPADA · 2020 to 2021
$550k
BLRD VA IK6 BX004982NIA NIH HHS R01 AG050431NIA NIH HHS R21 AG069229
6 · The paper itself

Abstract

backgroundDoublecortin (DCX), a microtubule associated protein, has emerged as a central biomarker of hippocampal neurogenesis. However, molecular mechanisms by which DCX is regulated are poorly understood.

objectiveSince sleep is involved with the acquisition of memory and oleamide or 9-Octadecenamide (OCT) is a sleep-inducing supplement in human, we examined whether OCT could upregulate DCX in hippocampal progenitor cells (HPCs).

methodsWe employed real-time PCR, western blot, immunostaining, chromatin immunoprecipitation, lentiviral transduction in HPCs, and the calcium influx assay.

resultsOCT directly upregulated the transcription of Dcx in HPCs via activation of peroxisome proliferator-activated receptor α (PPARα), a lipid-lowering transcription factor. We observed that, HPCs of Ppara-null mice displayed significant impairment in DCX expression and neuronal differentiation as compared to that of wild-type mice. Interestingly, treatment with OCT stimulated the differentiation process of HPCs in wild-type, but not Ppara-null mice. Reconstruction of PPARα in mouse Ppara-null HPCs restored the expression of DCX, which was further stimulated with OCT treatment. In contrast, a dominant-negative mutant of PPARα significantly attenuated the stimulatory effect of OCT on DCX expression and suppressed neuronal differentiation of human neural progenitor cells. Furthermore, RNA microarray, STRING, chromatin immunoprecipitation, site-directed mutagenesis, and promoter reporter assay have identified DCX as a new target of PPARα.

conclusionThese results indicate that OCT, a sleep supplement, directly controls the expression of DCX and suggest that OCT may be repurposed for stimulating the hippocampal neurogenesis.

Indexed as

Doublecortin Domain ProteinsPromoter Regions, GeneticUp-RegulationAnimalsCell DifferentiationFood AdditivesGene Expression RegulationHippocampusHumansMiceMice, KnockoutOleic AcidsPPAR alphaSleepSleep Aids, PharmaceuticalTranscription FactorsDoublecortin Domain ProteinsFood AdditivesOleic AcidsoleylamidePPAR alphaSleep Aids, PharmaceuticalTranscription FactorsDoublecortinhippocampal progenitor cellsoleamidePPARα

Identifiers

PMID34744082
PMCPMC10075226
OpenAlexW3208950961

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.